For research use only. Not for therapeutic Use.
AGI-24512 (Cat.No:I020088) is a potent and selective inhibitor of the tyrosine kinase receptor AXL. It shows promising results in preclinical studies for the treatment of a variety of cancers, including breast, lung, and ovarian cancer. AGI-24512 exhibits good oral bioavailability and pharmacokinetic properties and is being developed as an anticancer drug.
| Catalog Number | I020088 |
| CAS Number | 2201066-53-5 |
| Molecular Formula | C₂₄H₂₄N₄O₂ |
| Purity | ≥95% |
| IUPAC Name | 6-(4-hydroxyphenyl)-5-methyl-2-phenyl-3-piperidin-1-yl-1H-pyrazolo[1,5-a]pyrimidin-7-one |
| InChI | InChI=1S/C24H24N4O2/c1-16-20(17-10-12-19(29)13-11-17)24(30)28-23(25-16)22(27-14-6-3-7-15-27)21(26-28)18-8-4-2-5-9-18/h2,4-5,8-13,26,29H,3,6-7,14-15H2,1H3 |
| InChIKey | VFEXODVWKUOZBF-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=O)N2C(=N1)C(=C(N2)C3=CC=CC=C3)N4CCCCC4)C5=CC=C(C=C5)O |
| Reference | [1]. Agios. Targeting MAT2A in MTAP-deleted Cancers. Presented at the American Association for Cancer Research (AACR) Annual Meeting, April 14-18, 2018, Chicago, IL, USA |
